Country: Ireland
Bahasa: Inggeris
Sumber: HPRA (Health Products Regulatory Authority)
Ranitidine
Chefaro Ireland DAC
A02BA; A02BA02
Ranitidine
75 milligram(s)
Effervescent tablet
Product not subject to medical prescription
H2-receptor antagonists; ranitidine
Marketed
2000-12-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zantac 75 Dissolve 75mg Effervescent Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 75 mg ranitidine as ranitidine hydrochloride. Excipients: Each tablet contains 164.01mg of sodium, 15mg of aspartame and less than 15mg of sorbitol. _For a full list of excipients, see section 6.1._ 3 PHARMACEUTICAL FORM Effervescent tablet. White to pale yellow, round, flat bevel-edged tablet engraved ‘GX EK1’ on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS The short-term symptomatic relief of acid indigestion and heartburn. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION ADULTS: One Zantac 75 effervescent tablet should be dissolved in water (_see 6.6 Instructions for Use/Handling_) and taken when symptoms occur, day or night. Maximum intake in 24 hours: 2 tablets (150 mg). The maximum treatment period is two weeks. It is not necessary to take the tablets with food. Patients are advised to consult their doctor if symptoms persist, get worse or continue for 14 days. CHILDREN: The use of Zantac 75 Dissolve effervescent tablets in children under 16 years of age is not recommended. 4.3 CONTRAINDICATIONS Known hypersensitivity to ranitidine or any other component of the preparation. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Treatment with histamine H 2 -antagonist may mask symptoms associated with carcinoma of the stomach and may therefore delay diagnosis of the condition. SEVERE RENAL IMPAIRMENT Ranitidine is excreted through the kidney and so plasma levels of the drug are increased in patients with severe renal impairment. Zantac 75 Dissolve effervescent tablets are not suitable for these patients. I R I S H M E D I C I N E S B O A R D ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Baca dokumen lengkap